PCM
HAE icon

Palisade Capital Management’s Haemonetics HAE Stock Holding History

Palisade Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,000
Closed -$424K – 430
2021
Q3 		$424K Sell
6,000
-2,250
-27% -$142K 0.01% 361
2021
Q2 		$550K Buy
+8,250
New +$584K 0.01% 353

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
LCP
LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Palisade Capital Management's HAE Position: Q4 2021 in Review

Palisade Capital Management sold out of Haemonetics (HAE) in Q4 2021, closing a stake of 6,000 shares — an estimated $424K sold.

Palisade Capital Management first reported a position in HAE in Q2 2021 and held it in 2 quarters. The position peaked at $550K in Q2 2021. 257 funds tracked by Wall St. Rank hold HAE as of Q4 2021.

  • Palisade Capital Management reported no remaining Haemonetics position as of Q4 2021 after selling out during the quarter.
  • Palisade Capital Management sold 6,000 Haemonetics shares in Q4 2021, an estimated $424K.
  • Palisade Capital Management first reported a position in Haemonetics in Q2 2021 and held it in 2 quarters.
  • Palisade Capital Management's Haemonetics position peaked at $550K in Q2 2021.
  • 257 funds tracked by Wall St. Rank held Haemonetics as of Q4 2021.

Based on Palisade Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.